Search

Your search keyword '"Cheng, Guang‐Shing"' showing total 405 results

Search Constraints

Start Over You searched for: Author "Cheng, Guang‐Shing" Remove constraint Author: "Cheng, Guang‐Shing"
405 results on '"Cheng, Guang‐Shing"'

Search Results

51. Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir.

53. Contributors

60. Infectious Complications after Intensive Chemotherapy with CLAG-M or '7+3' for Adults with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

65. Clinical and Virologic Characteristics and Outcomes of Coronavirus Disease 2019 at a Cancer Center

66. Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary

67. Immune Correlates from a Prospective Trial Suggest Leukotriene Signaling and Alternative Macrophage Activation in Clinical Bronchiolitis Obliterans Syndrome

68. Which Respiratory Virus Infections Are Associated with Increased Risk of Specific Bacterial Infection in Allogeneic Hematopoietic Cell Transplant Recipients?

69. To Toci or Not to Toci for COVID-19: Is That Still the Question?

70. Multicenter evaluation of parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

71. Prospective Phase Ii Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bos Pathogenesis

74. Colaboradores

76. Tocilizumab in hospitalized patients with COVID‐19: Clinical outcomes, inflammatory marker kinetics, and safety

77. Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients

78. Feasibility of home spirometry in patients with chronic graft-versus-host disease: a prospective observational study

79. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, safety, and a review of the literature

82. Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts

84. A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients

87. Contributors

88. Predictive Value of Respiratory Viral Detection in the Upper Respiratory Tract for Infection of the Lower Respiratory Tract With Hematopoietic Stem Cell Transplantation

90. Early Respiratory Viral Acquisition after Allogeneic Hematopoietic Cell Transplant (HCT)

91. Human Metapneumovirus or Influenza A Upper Respiratory Tract Infection Associated with Increased Risk of Bacterial Superinfection in Allogeneic Hematopoietic Cell Transplant Recipients

92. Tocilizumab in hospitalized patients with COVID‐19: Clinical outcomes, inflammatory marker kinetics, and safety.

95. A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients.

97. 85 - Immune Correlates from a Prospective Trial Suggest Leukotriene Signaling and Alternative Macrophage Activation in Clinical Bronchiolitis Obliterans Syndrome

98. Predictive Value of Respiratory Viral Detection in the Upper Respiratory Tract for Infection of the Lower Respiratory Tract With Hematopoietic Stem Cell Transplantation.

99. Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation

100. 750. Respiratory Virus Infections and Airflow Obstruction After Allogeneic Hematopoietic Cell Transplantation

Catalog

Books, media, physical & digital resources